HIP Fracture Accelerated Surgical TreaTment And Care tracK (HIP ATTACK) Trial
| Status: | Recruiting |
|---|---|
| Conditions: | Orthopedic, Orthopedic |
| Therapuetic Areas: | Orthopedics / Podiatry |
| Healthy: | No |
| Age Range: | 45 - Any |
| Updated: | 6/2/2018 |
| Start Date: | March 2014 |
| End Date: | April 2020 |
| Contact: | Jessica Vincent, MSc |
| Email: | jessica.vincent@phri.ca |
| Phone: | 905-527-4322 |
HIP ATTACK is an international randomized controlled trial of 3000 patients with a hip
fracture that requires a surgical intervention. This trial will determine the effect of
accelerated medical clearance and accelerated surgery compared to standard care on the 90-day
risk of mortality and major perioperative complication (i.e., a composite of mortality,
nonfatal myocardial infarction, nonfatal pulmonary embolism, nonfatal pneumonia, nonfatal
sepsis, nonfatal stroke, and nonfatal life-threatening and major bleeding).
fracture that requires a surgical intervention. This trial will determine the effect of
accelerated medical clearance and accelerated surgery compared to standard care on the 90-day
risk of mortality and major perioperative complication (i.e., a composite of mortality,
nonfatal myocardial infarction, nonfatal pulmonary embolism, nonfatal pneumonia, nonfatal
sepsis, nonfatal stroke, and nonfatal life-threatening and major bleeding).
Inclusion Criteria:
- age ≥45 years; and
- diagnosis of hip fracture during working hours with a low-energy mechanism (i.e.,
falling from standing height) requiring surgery.
Exclusion Criteria:
- patients requiring emergent surgery or emergent interventions for another reason
(e.g., subdural hematoma, abdominal pathology requiring urgent laparotomy, acute limb
ischemia, other fractures or trauma requiring emergent surgery, necrotising fasciitis,
coronary revascularization, pacemaker-implantation);
- open hip fracture;
- bilateral hip fractures;
- peri-prosthetic fracture;
- therapeutic anticoagulation not induced by a Vitamin K Antagonist, unfractionated
heparin, (e.g., administration of therapeutic Low Molecular Weight Heparin (LMWH)
(>6,000 u/24h) in the 24 hours prior to enrolment, or intake of any other
non-reversible oral anticoagulant(s) for which there is no reversing agent available
- patients on a therapeutic vitamin K antagonist with a history of heparin induced
thrombocytopenia (HIT);
- patients refusing participation; or
- patients previously enrolled in the study.
We found this trial at
4
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials